Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 7/20 | 0.39 |
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16383317 | 0.84 | HRH4 (0.38) | HRH4NOS3NOS1NOS2NPC1 | |
| SCHEMBL13816110 | 0.82 | NOS3 (0.52) | HRH4NOS3NOS1NOS2NPC1 | |
| SCHEMBL35018 | 0.81 | HRH4 (0.36) | HRH4NOS3NOS1NOS2NPC1 | |
| SCHEMBL16186888 | 0.80 | MAPT (0.44) | RAB9AALDH1A1MAPTPKMSMN1; SMN2 | |
| SCHEMBL16383318 | 0.79 | NOS3 (0.39) | HRH4NOS3NOS1NOS2NPC1 | |
| SCHEMBL24611380 | 0.77 | CTSD (0.41) | NPC1RAB9AALDH1A1MAPTPKM | |
| SCHEMBL2756155 | 0.75 | NPSR1 (0.36) | NPC1RAB9AALDH1A1SMN1; SMN2TRPA1 | |
| SCHEMBL22087220 | 0.75 | RAB9A (0.42) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL13160611 | 0.75 | KDM4E (0.42) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL14440660 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230365570-A1 | COMPOUNDS WITH GLUCOCORTICOID SPARING EFFECTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4248973-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230255963-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11725003-B2 | Amine derivative and an organic electroluminescent device thereof | CHANGCHUN HYPERIONS TECHNOLOGY CO., LTD (CN) | 2023-08-15 | — | — | US | disclosed |
| US-7511039-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7459457-B2 | Polycyclic pyridines as potassium ion channel modulators | ICAGEN, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20070161578-A1 | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | SCHERING CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| EP-0540956-A1 | Process for the manufacture of substituted maleimides | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-12 | — | — | EP | disclosed |
| EP-0382618-A2 | Aminoalkoxyphenyl derivatives, process for their preparation and compositions containing them | SANOFI (FR) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSME1, PSME4 | HRH4 3061/4885NOS3 3724/4885NOS1 3368/4885 |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | HRH4 1156/4885NOS3 2866/4885NOS1 3050/4885 |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | HRH4 5/4885NOS3 1921/4885NOS1 2677/4885 |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | HRH4 4847/4885NOS3 2981/4885NOS1 3527/4885 |
| US-20230255963-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | HRH4 1023/4885NOS3 243/4885NOS1 439/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | HRH4 2171/4885NOS3 3461/4885NOS1 3625/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | HRH4 1939/4885NOS3 2896/4885NOS1 3773/4885 |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | HRH4 1716/4885NOS3 4477/4885NOS1 4432/4885 |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | MAOA, DRD2, MAOB | HRH4 665/4885NOS3 1606/4885NOS1 1259/4885 |
| US-20070099944-A1 | Chemical compounds | ROCK1, ROCK2, CIT | HRH4 1449/4885NOS3 399/4885NOS1 212/4885 |
| US-11725003-B2 | Amine derivative and an organic electroluminescent device thereof | AOC1, AOX1, AOC2 | HRH4 2623/4885NOS3 1262/4885NOS1 1187/4885 |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | SERPINB1, SERPINE1, SERPINA2 | HRH4 4499/4885NOS3 3460/4885NOS1 2914/4885 |
| US-20230365570-A1 | COMPOUNDS WITH GLUCOCORTICOID SPARING EFFECTS AND USES THEREOF | NR3C1, NR3C2, NR5A1 | HRH4 508/4885NOS3 524/4885NOS1 641/4885 |
| US-20070161578-A1 | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | NR1H4, NR1H3, NR1H2 | HRH4 13/4885NOS3 2094/4885NOS1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.